Increase in primary liver cancer in the UK, 1979-94
Increase in primary liver cancer in the UK, 1979-94
复制标题
DOI:
10.1016/s0140-6736(05)63789-0
复制
发表时间:
1997-10-18
期刊:
影响因子:
168.9
通讯作者:
Thomas, HC
中科院分区:
文献类型:
--
作者:
TaylorRobinson, SD;Foster, GR;Thomas, HC
Advances in tissue bioengineering, such as the development of biologically useful cells, tissue, and organs, are expected to revolutionise the practice of medicine. 1 Living skin equivalent (LSE), a bioengineered skin, is composed of an epidermis and dermis made of type I bovine collagen and cultured allogeneic cells (keratinocytes and fibroblasts) isolated from human neonatal foreskin. In controlled studies, LSE improved healing in venous ulcers2 and in open studies it seemed to improve healing in thermal burns and acute wounds created by excision of skin cancer. 3 We report a prospective, randomised, paired comparison of SEL splitthickness autograft, and polyurethane film (PUF) occlusion dressing for the treatment of split-thickness skin graft donor sites.Three 2· 5 cm4· 0 cm donor sites were created on the anterior thigh of 11 patients who required split-thickness skin grafts. Each patient’s donor sites were randomly treated with meshed LSE, meshed autograft, or PUF. Evaluations were on day 7, every 2–3 days thereafter until healing of all three donor sites, and at 1 and 2 months. Endpoints were time to healing, pain, and cosmetic outcome (pigmentation, vascularity, and height). The mean time to healing was 7· 4 days (SD 0· 9) for LSE, 7· 9 days (1· 5) for autograft, and 10· 4 days (1· 7) for PUF (p= 0· 0006). In addition to rapid healing, LSE and autograft reduced the pain associated with healing donor sites. No patients experienced pain with LSE or with autograft compared with PUF which was associated with mild pain in six of ten patients. LSE and autograft afforded a more desirable cosmetic result. At 2 months all sites were hyperpigmented, but the vascularity was different. LSE was pink, autograft was normal, and PUF was purple. The PUF sites were evaluated in eight of 19 patients at 2 months. There was a 90% incidence of clinical take and no signs of toxicity or clinically detectable rejection to LSE in the patients enrolled in this study. Our observations are consistent with those reported using LSE for the treatment of acute wounds after Mohs surgery. 4